The role of STI-571 in the treatment of EAE
-
1
Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Iran
-
2
Tehran University of Medical Sciences, Iran
Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that leads to an inflammatory demyelination, axonal damage and progressive neurologic disability. STI-571 is a selective protein tyrosine kinase inhibitor that abrogates multiple signal transduction pathways implicated in auto immune diseases.
Method: EAE induction was performed by Hooke Kit. The kit consists of antigen (MOG35-55) in CFA emulsion, and pertussis toxin (PTX) in PBS. The mice were injected subcutaneously on upper back and lower back with 0.1 ml of emulsion respectively. Within 2 hours of injection of the emulsion, the first dose of PTX (0.1 ml per mouse) was injected intraperitoneally. 22-26 hours after injection of the emulsion, the intraperitoneally injection of second dose of PTX into the mice (0.1 ml) were done. The mice were administered orally with STI-571 at the specified dose (60 mg/kg) from day 7 after immunization on six consecutive d per wk for 2 wk. The mice were sacrificed on day 35 post-immunization. Brains, cerebellums and lumbar spinal cords were removed, post-fixed in formalin, embedded in paraffin, sectioned and then stained with Luxol fast blue (LFB) and with eosin and hematoxylin.
RESULTS: Our findings showed that treatment with STI-571 caused a significant delay in the time of onset and a significant reduction in severity of the EAE in treated animals compared with normal groups.
Conclusion: Our results suggest that FDA-approved drug STI-571 has potential therapeutic effects on EAE as an autoimmune demyelinating disease.
Keywords:
EAE,
STI-571,
MS,
CNS,
Autoimmune
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Immune-mediated disease pathogenesis
Citation:
Azizi
G and
Mirshafiey
A
(2013). The role of STI-571 in the treatment of EAE.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00577
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
04 Jun 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Ms. Gholamreza Azizi, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, karaj, Iran, azizi1357g@gmail.com